Long Term Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Subjects [EXTENSION OF PROFILE 700021577].
Latest Information Update: 09 Dec 2023
At a glance
- Drugs GSK 137173A (Primary)
- Indications Herpes zoster
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 30 Sep 2015 Results published in the Vaccine.
- 21 Sep 2013 Planned number of patients changed from 166 to 167 as reported by European Clinical Trials Database record.
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.